Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-758-7 | CAS number: 87-62-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
Toxicokinetics
2,6-Xylidine is a chemical intermediate used principally in the production of dyes. It is also a component of tobacco smoke, a degradation product of aniline-based pesticides, and a metabolite of certain drugs, particularly the xylide group of local anesthetics.
2,6-Xylidine is easily absorbed from the gastro-intestinal tract and excreted unchanged or metabolized via the urine in experimental animals. 2,6-xylidine produces only weak methaemoglobin formation.
Absorption
2,6-Xylidine is absorbed from the small intestine in rats, the half life periods for this process being 14.4 minutes (no further details; Pla' Delfina, et al., 1972). Further studies dealing specifically with absorption of the xylidines are not available. Proof of absorption following oral application of 2,6-xylidine in rats, and following oral application of 2,6-xylidine in dogs, has been furnished by the detection of the xylidines and their corresponding metabolites in the urine (Hardy et al., Short et al).
Poisoning symptoms, which have been described following corresponding applications, suggest that absorption via the skin and the respiratory tract may take place.
Distribution
No studies or results are available for tissue distribution in animals.
Metabolism
The results of studies on the metabolism of the xylidines following oral application are given in shortened form in the following table. In general, investigations with different species show the same main metabolites after hydroxylation of 2,6-xylidine.
Species |
Metabolite |
Conjugate of the metabolite |
Literature |
rat |
2,6-xylidine unchanged 4-hydroxy-2,6-xylidine 2-amino-3-methyl benzoic acid |
not specified |
Lindstromet al.(1963) |
rat |
2,6-xylidine unchanged 4-hydroxy-2,6-xylidine N,2,5-trimethyl aniline |
glucuronide, sulphate glucuronide, sulphate |
Shortet al.(1989) |
dog |
2,6-xylidine unchanged 4-hydroxy-2,6-xylidine 2-amino-3-methyl benzoic acid N,2,6-trimethyl-aniline 2,6-dimethyl-nitrosobenzene 4-imino-3,5-methylquinone |
glycine |
Shortet al.(1989) |
In the study by Lindstromet al.(1963) 2,6-xylidine was given to male Osborne-Mendel rats at a dose of 20 mg/kg body weight in water by gavage. Apart from the initial substance and non-specified conjugates, the urine analysis resulted in mainly the 4-hydroxy-2,6-xylidine and, in lower concentration, the 2-amino-3-methyl benzoic acid as excretion products.
Shortet al.(1989a) examined the metabolism of rats. 16 male (12 week-old) Fischer-344 rats were treated with 2,6-xylidine (purity > 99%) in corn oil by gavage at a dose of 262.5 mg/kg body weight (1/4 of the LD50) for 10 days. 3 further groups, each consisting of 16 male Fischer-344 rats, were given intraperitoneal injections of either 80 mg phenobarbital/kg body weight, 15 mg methylcholanthrene/kg body weight or 50 mg SKF-525A/kg body weight daily for 10 days, in addition to the 2,6-xylidine treatment. Pooled 24-hour urine samples were analysed from day 1 and day 10. Analysis of the urine gave, apart from the initial substance, 4-hydroxy-2,6-xylidine and the sulphate and glucuronic conjugates of both substances. N,2,6-trimethylaniline was found in low concentration. The duration of treatment had no qualitative or significant quantitative effect on the metabolism. In the same study, following administration of 2,6-xylidine to dogs, apart from the initial substance, 4-hydroxy-2,6-xylidine was mainly found and, in lower quantities, 2-amino-3-methyl benzoic acid and its glycine conjugate, N,2,6-trimnethylaniline, 2,6-dimetbylnitrosabenzene and 4-imino-3,5-dimethylquinone. The quantity of different metabolites was subject to considerable individual variations. The longer treatment had no effect.
Excretion
In all the investigations on metabolism of the xylidines following oral application mentioned in this section, the possibility of excretion of the xylidines or their metabolites through breathing or through the faeces was not examined.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.